Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Executive SummaryFailure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
You may also be interested in...
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.